Anika Therapeutics Inc.

39.28+0.1700+0.43%Vol 28.20K1Y Perf 21.25%
Sep 23rd, 2021 14:08 DELAYED
BID39.26 ASK39.35
Open39.19 Previous Close39.11
Pre-Market- After-Market-
 - -%  - -
Target Price
45.00 
Analyst Rating
Moderate Buy 1.67
Potential %
14.56 
Finscreener Ranking
★★★★+     55.62
Insiders Trans % 3/6/12 mo.
100/50/- 
Value Ranking
★★★     51.88
Insiders Value % 3/6/12 mo.
100/46/-19 
Growth Ranking
★★+     48.02
Insiders Shares Cnt. % 3/6/12 mo.
100/48/-22 
Income Ranking
 —    -
Price Range Ratio 52W %
44.34 
Earnings Rating
Strong Buy
Market Cap566.54M 
Earnings Date
3rd Nov 2021
Alpha-0.01 Standard Deviation0.13
Beta1.24 

Today's Price Range

39.1039.54

52W Range

32.0448.37

5 Year PE Ratio Range

11.6059.20

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-1.49%
1 Month
-9.24%
3 Months
-10.17%
6 Months
15.03%
1 Year
21.25%
3 Years
-4.66%
5 Years
-16.65%
10 Years
620.26%

TickerPriceChg.Chg.%
ANIK39.280.17000.43
AAPL146.911.06000.73
GOOG2 840.0021.23000.75
MSFT299.871.29000.43
XOM57.061.85003.35
WFC48.050.97002.06
JNJ165.661.73001.06
FB346.633.42001.00
GE103.675.13005.21
JPM161.555.64003.62
Financial StrengthValueIndustryS&P 500US Markets
3.10
4.30
0.07
0.08
-
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
55.50
-13.10
-2.80
17.60
-9.00
RevenueValueIndustryS&P 500US Markets
136.82M
9.49
7.69
4.82
Earnings HistoryEstimateReportedSurprise %
Q02 20210.040.09125.00
Q01 20210.010.06500.00
Q04 20200.110.129.09
Q03 20200.13-0.45-446.15
Q02 2020-0.210.09142.86
Q01 20200.400.4512.50
Q04 20190.410.434.88
Q03 20190.410.6456.10
Earnings Per EndEstimateRevision %Trend
9/2021 QR0.0814.29Positive
12/2021 QR0.11-8.33Negative
12/2021 FY0.3313.79Positive
12/2022 FY0.48-9.43Negative
Next Report Date3rd Nov 2021
Estimated EPS Next Report0.08
Estimates Count1
EPS Growth Next 5 Years %10.00
Volume Overview
Volume28.20K
Shares Outstanding14.42M
Shares Float10.54M
Trades Count702
Dollar Volume6.39M
Avg. Volume110.25K
Avg. Weekly Volume120.19K
Avg. Monthly Volume81.19K
Avg. Quarterly Volume71.56K

Anika Therapeutics Inc. (NASDAQ: ANIK) stock closed at 39.11 per share at the end of the most recent trading day (a 0.93% change compared to the prior day closing price) with a volume of 80.09K shares and market capitalization of 566.54M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 154 people. Anika Therapeutics Inc. CEO is Cheryl R. Blanchard.

The one-year performance of Anika Therapeutics Inc. stock is 21.25%, while year-to-date (YTD) performance is -13.59%. ANIK stock has a five-year performance of -16.65%. Its 52-week range is between 32.04 and 48.37, which gives ANIK stock a 52-week price range ratio of 44.34%

Anika Therapeutics Inc. currently has a PE ratio of -44.10, a price-to-book (PB) ratio of 2.00, a price-to-sale (PS) ratio of 4.12, a price to cashflow ratio of 55.40, a PEG ratio of 2.32, a ROA of -3.07%, a ROC of -3.79% and a ROE of -4.30%. The company’s profit margin is -9.00%, its EBITDA margin is -2.80%, and its revenue ttm is $136.82 Million , which makes it $9.49 revenue per share.

Of the last four earnings reports from Anika Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.08 for the next earnings report. Anika Therapeutics Inc.’s next earnings report date is 03rd Nov 2021.

The consensus rating of Wall Street analysts for Anika Therapeutics Inc. is Moderate Buy (1.67), with a target price of $45, which is +14.56% compared to the current price. The earnings rating for Anika Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Anika Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Anika Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.98, ATR14 : 1.05, CCI20 : -90.97, Chaikin Money Flow : -0.38, MACD : -0.68, Money Flow Index : 38.94, ROC : -3.60, RSI : 38.70, STOCH (14,3) : 12.12, STOCH RSI : 0.33, UO : 36.93, Williams %R : -87.89), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Anika Therapeutics Inc. in the last 12-months were: Cheryl R. Blanchard (Option Excercise at a value of $100 000), David Colleran (Option Excercise at a value of $0), James Loerop (Option Excercise at a value of $0), John B. Henneman (Buy at a value of $85 720), Michael L. Levitz (Buy at a value of $145 826), Michael L. Levitz (Option Excercise at a value of $0), Raymond J. Land (Sold 8 892 shares of value $338 619 ), Thomas Finnerty (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
2 (66.67 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (33.33 %)
1 (33.33 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.67
Strong Buy
1.00

Anika Therapeutics Inc.

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company's product profile includes Orthobiologics, Dermal, Surgical and other of which Orthobiologics products generates maximum revenue to the company.

CEO: Cheryl R. Blanchard

Telephone: +1 781 457-9000

Address: 32 Wiggins Avenue, Bedford 01730, MA, US

Number of employees: 154

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

58%42%

Bearish Bullish

63%37%

TipRanks News for ANIK

News

Stocktwits